Dr Tobias Menne is a Haematologist specialising in acute lymphoblastic leukaemia, lymphoma and CAR-T cell therapies. He is the Clinical Director for Research.
Since September 2021 Dr Menne is the Clinical Director for Research at our trust. He is the regional sub-speciality research lead for haemato-oncology, clinical haem/onc research lead and lead for immune effector cell therapy in the Newcastle upon Tyne Hospitals NHS Foundation Trust. He is a member of the national Lymphoma Clinical Study Group and the national Low Grade and High Grade Lymphoma Working Groups and the Adult Acute Lymphoblastic Leukaemia Working Group.
Dr Menne studied Medicine at the Free University in Berlin before undertaking specialist training in haematology in the UK (St Thomas’ Hospital, London and Ipswich Hospital and Addenbrooke’s Hospital, Cambridge). After completing a PhD at Cambridge University under the supervison of Professor Alan Warren in 2006, Dr Menne spent four years at Harvard Children’s Hospital in Boston, USA as a post-doctoral researcher in Professor Stuart Orkin’s laboratory before joining the Freeman Hospital as a Consultant Haematologist in October 2010.
Special interests
Acute lymphoblastic leukaemia, lymphoma, CAR-T cell therapies, clinical research
Research
He has a special interest in lymphoma and acute lymphoblastic leukaemia. He is actively involved in clinical research. Dr Menne is Chief Investigator on the TIDaL (testing upfront ibrutinib and rituximab therapy in PTLD) and SELUDex trials (testing the MEK inhibitor Selumetinib in R/R ALL), as well as a member of the Trial Management Group for UKALL14 , PETReA trials and the upcoming UKALL15, and POLARICE trials. He is PI on several CAR-T cell studies in lymphoma and myeloma.
